Origin Genomics, a New York City biotech startup founded by entrepreneur Cathy Tie, is advancing research on gene-editing in human embryos aimed at preventing inherited diseases. Although current US laws strictly prohibit creating gene-edited babies through implantation, the company is testing techniques in embryos to explore whether gene editing could safely correct mutations linked to conditions such as cystic fibrosis, Huntington’s disease, hereditary cancers, and beta thalassemia.
Tie told NPR during a recent interview, “What we are proposing is something completely revolutionary: Apply this amazing precision genome editing to embryos that have a mutation before they are born.” She emphasised the company’s focus on disease prevention, not genetic enhancement, adding, “This is a very powerful technology. Safety must come first.” Origin Genomics publicly commits to transparency and ethics oversight, operating within applicable US federal and state regulations.
US regulations clear forbid gene editing for reproductive purposes. Since 2015, congressional restrictions have blocked the Food and Drug Administration from considering clinical applications that involve heritable genetic modification. The Guardian and Le Monde report that while research on embryos not intended for implantation is permitted in laboratories, implanting gene-edited embryos to create babies remains illegal across the United States.
Many scientists consider gene-edited reproduction premature and unsafe at this stage. However, some bioethicists argue emerging gene-editing tools could eventually offer safer methods to prevent severe genetic diseases before birth. Cathy Tie noted, “We want to be the company that does this in the light, with transparency and with good intentions.” Conversely, critics like Tim Hunt, CEO of the Alliance for Regenerative Medicine, dismiss heritable gene editing as “a terrible solution in search of a problem.”
The research landscape is actively evolving but marked by caution. Origin Genomics was founded in March 2026, after Tie closed her previous biotech venture. The company plans to advance embryo editing under independent ethics oversight. However, no verified claims exist that any gene-edited embryo has been implanted or that regulatory approval for clinical use is forthcoming. The debate continues over whether US law should adapt to permit gene-edited babies if safety standards can be assured.
For South African readers, this development parallels ongoing global discussions on gene editing ethics, regulation, and potential disease prevention. While the science holds promise for tackling inherited illnesses, legal barriers and bioethical concerns remain formidable. Origin Genomics’s research highlights the tension between innovation and regulation that shapes the future of human genetic medicine worldwide.
CapeFlats.co.za will monitor regulatory updates, scientific progress, and ethical debates surrounding gene editing technologies as they develop.